MG
ADMS

Michael Gelband’s Adamas Pharmaceuticals ADMS Stock Holding History

Michael Gelband’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39,618
Closed -$190K – 3030
2021
Q1 		$190K Buy
+39,618
New +$207K ﹤0.01% 1885

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Michael Gelband's ADMS Position: Q2 2021 in Review

Michael Gelband sold out of Adamas Pharmaceuticals (ADMS) in Q2 2021, closing a stake of 39,618 shares — an estimated $190K sold.

Michael Gelband first reported a position in ADMS in Q1 2021 and held it in 1 quarter. The position peaked at $190K in Q1 2021. 67 funds tracked by Wall St. Rank hold ADMS as of Q2 2021.

  • Michael Gelband reported no remaining Adamas Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Michael Gelband sold 39,618 Adamas Pharmaceuticals shares in Q2 2021, an estimated $190K.
  • Michael Gelband first reported a position in Adamas Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Michael Gelband's Adamas Pharmaceuticals position peaked at $190K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2021.

Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.